着床前遺伝子検査市場：検査実施タイプ、検査タイプ、技術タイプ、オファリング、エンドユーザー別- 世界予測2025～2030年

着床前遺伝子検査市場の2024年の市場規模は7億8,019万米ドルで、2025年には8億7,374万米ドル、CAGR12.23%で成長し、2030年には15億5,987万米ドルに達すると予測されています。

着床前遺伝学的検査（PGT）は、生殖医療における変革の柱として登場し、ヒトの発育の初期段階において希望と明瞭さを提供しています。遺伝子スクリーニングと診断技術の進歩により、着床前に潜在的な遺伝子異常を特定することが可能になり、それによって遺伝性疾患のリスクを軽減し、より健康的な結果を保証することができるようになりました。この開発は、個別化医療と標的診断の需要が高まっている時代において特に重要です。

PGT技術の進化は、増え続ける臨床研究、検査技術の向上、バイオテクノロジー企業と医療機関の協力関係の強化によって推進されています。不妊治療クリニックと診断ラボの両方が最先端の遺伝子スクリーニングツールを取り入れるにつれて、状況は急速に進化しており、技術革新はアクセス性と効率性の向上に繋がっています。このダイナミックな環境において、利害関係者は強固な遺伝子検査プロトコルを探求し、親と胚の遺伝学における最新の知見を活用した統合的戦略を採用することが奨励されています。

こうして市場は上昇軌道に乗り、研究イニシアチブを強化し、生殖医療へのより包括的なアプローチを可能にしています。技術の飛躍的進歩のたびに、不妊治療における安全性の向上と成功率の向上が約束され、臨床医にとっても患者にとっても、ますます実現可能性が高まっています。

着床前遺伝子検査市場の変革

近年、着床前遺伝学的検査市場の輪郭を再定義するような、一連の変革的変化が起こっています。産業は、遺伝子スクリーニングの精度と信頼性を大幅に向上させる最先端の技術と手法を受け入れてきました。歴史的に標準的な細胞遺伝学的手法に依存してきたこのセグメントは、現在では高解像度のゲノムツールを取り入れ、診断精度とスループットのパラダイムシフトにつながっています。

最も注目すべき進歩の一つは、次世代シーケンサーの統合です。この技術は、軽微な染色体異常の検出を向上させるだけでなく、複数の遺伝子疾患を同時に、比類ない精度で検査することを可能にします。さらに、従来のポリメラーゼ連鎖反応（PCR）ベースの検査から、より洗練されたゲノムハイブリダイゼーション技術への進化は、臨床的信頼性を高める環境を育んできました。

世界規模での規制の枠組みも、こうした進歩に対応するように変化しています。新しいガイドラインでは、ゲノムの完全性の重要性と、包括的で忠実度の高い着床前検査の必要性を認めるようになってきています。さらに、公的研究機関と民間企業との協力関係の改善は、産業全体の相乗効果をもたらし、さらなる技術革新に拍車をかけています。このようなパラダイムシフトの結果、市場は、より高い有効性、オーダーメイドの治療方法、患者の転帰の改善の時代へと向かっています。

着床前遺伝子検査市場の主要セグメンテーション洞察

市場セグメンテーションを詳細に検討すると、多様な検査技術、先進技術、多様な最終用途を反映した、微妙な状況が明らかになります。検査タイプによるセグメンテーションでは、異数性調査を対象とするPGT-A、単原性障害の検出に焦点を当てたPGT-M、構造再配列を分析するように設計されたPGT-SRにわたって市場を調査します。各カテゴリーは、効果的な診断に必要とされる特異性と精度によって、独自の課題と機会を示しています。

さらに、検査タイプによる区分は、主にハイリスクのカップルにおける既知の遺伝的異常または染色体異常を検出するために採用される着床前遺伝子診断と、胚における潜在的な遺伝的異常のより広範な調査を提供する着床前遺伝子スクリーニングを区別します。この2つのアプローチにより、幅広い遺伝的疾患が効果的にスクリーニングされ、多様な患者のニーズに合わせたソリューションが提供されます。

技術の領域では、市場セグメンテーションは、比較ゲノムハイブリダイゼーションや蛍光in-situハイブリダイゼーションから、次世代シーケンス、PCRベースの検査、一塩基多型分析まで、さまざまな手法をカバーしています。これらの手法の進歩は、遺伝子検査法の精度、拡大性、手頃な価格を著しく向上させています。高性能技術への依存の高まりは、診断精度を高めただけでなく、さらなる科学的革新への道を開いた。

もう一つの重要な側面は、機器、試薬、消耗品、専用ソフトウェアというレンズを通して市場を精査する、製品によるセグメンテーションです。これらのコンポーネントは、検査プロセスのバックボーンを形成しており、各セグメントにおける進歩は、自動化とデータ分析における先進的な動向を裏付けています。

最後に、エンドユーザーの視点から考えると、市場は診断ラボ、不妊治療クリニック、病院、研究機関にわたって調査されています。このセグメンテーションは、多様な事業体が臨床効率と技術的洗練性のバランスをますます追求する中、PGT技術の幅広い採用を補強するものです。このような多面的なセグメンテーションモデルを理解することで、利害関係者は市場動向を把握し、戦略的に資源を配分し、生殖医療の重要なセグメントでさらなるイノベーションを推進することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中の医療インフラの改善と遺伝子検査施設へのアクセスの容易化
    • 体外受精（IVF）処置の需要増加着床前遺伝子検査
    • 将来の親たちの間で遺伝性疾患とその予防についての意識を高める
  • 抑制要因
    • 着床前遺伝子検査手続きの高コストにより、広範なアクセスと採用が制限される
  • 機会
    • 着床前遺伝子検査の精度と速度を向上させる技術の進歩
    • 体外受精クリニックとの提携によるバンドルサービスの提供
  • 課題
    • さまざまな地域の規制や倫理基準の遵守
• 市場セグメンテーション分析
  • 検査実施タイプ：遺伝性疾患の伝染を防ぐためのPGT-Mの必要性が高まっている
  • エンドユーザー：体外受精の成功率を高めるために不妊治療クリニックで着床前遺伝子検査の利用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 着床前遺伝子検査市場：検査実施タイプ別

• イントロダクション
• PGT-A（異数性）
• PGT-M（単一遺伝子疾患）
• PGT-SR（構造再編成）

第7章 着床前遺伝子検査市場：検査タイプ別

• イントロダクション
• 着床前遺伝子診断
• 着床前遺伝子スクリーニング

第8章 着床前遺伝子検査市場：技術タイプ別

• イントロダクション
• 比較ゲノムハイブリダイゼーション
• 蛍光in-situハイブリダイゼーション
• 次世代シーケンス
• PCR検査
• 一塩基多型

第9章 着床前遺伝子検査市場：オファリング別

• イントロダクション
• 機器
• 試薬と消耗品
• ソフトウェア

第10章 着床前遺伝子検査市場：エンドユーザー別

• イントロダクション
• 診断ラボ
• 不妊治療クリニック
• 病院
• 研究機関

第11章 南北アメリカの着床前遺伝子検査市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の着床前遺伝子検査市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの着床前遺伝子検査市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Techne Corporation
• Bioarray S.L.
• EUROPE IVF International s.r.o.
• F. Hoffmann-La Roche AG
• Genea Limited
• GENETiKS
• Illumina, Inc.
• Invicta Genetics
• Invitae Corporation
• Juno Genetics, US Inc.
• Laboratory Corporation of America Holdings
• MedGenome Labs Ltd.
• Merck KGaA
• Natera, Inc.
• NextGen Genetics Holdings, LLC
• Ovation Fertility
• PacGenomics
• PerkinElmer, Inc.
• Progyny, Inc.
• Qiagen N.V.
• Quest Diagnostics Incorporated
• Reproductive Genetic Innovations, LLC
• SEQUENCE46, LLC
• Sysmex Corporation
• Takara Bio Inc.
• The Cooper Companies Inc.
• Thermo Fisher Scientific Inc.
• Vitrolife Sweden AB
• Yikon Genomics（Shanghai）Co., Ltd.

LIST OF FIGURES

• FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET MULTI-CURRENCY
• FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET MULTI-LANGUAGE
• FIGURE 3. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
• FIGURE 4. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 76. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 81. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 167. ITALY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 187. POLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 192. QATAR PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 239. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

The Preimplantation Genetic Testing Market was valued at USD 780.19 million in 2024 and is projected to grow to USD 873.74 million in 2025, with a CAGR of 12.23%, reaching USD 1,559.87 million by 2030.

Preimplantation Genetic Testing (PGT) has emerged as a transformative pillar in reproductive medicine, offering hope and clarity at the earliest stages of human development. Advances in genetic screening and diagnostic techniques have made it possible to identify potential genetic anomalies before implantation, thereby mitigating the risk of inherited disorders and ensuring healthier outcomes. This development is particularly significant in an era where the demand for personalized medicine and targeted diagnostics is intensifying.

The evolution in PGT technologies is driven by an ever-growing body of clinical research, improvements in laboratory techniques, and increased collaboration among biotechnology firms and healthcare institutions. As both fertility clinics and diagnostic laboratories incorporate state-of-the-art genetic screening tools, the landscape is evolving rapidly, with innovation leading to greater accessibility and efficiency. In this dynamic environment, stakeholders are encouraged to explore robust genetic testing protocols and adopt integrative strategies that leverage the latest insights in parental and embryonic genetics.

The market has thus witnessed an upward trajectory, bolstering research initiatives and enabling a more comprehensive approach to reproductive health. With each technological breakthrough, the promise of improved safety and higher success rates in fertility treatments becomes increasingly attainable for clinicians and patients alike.

Transformative Shifts in the Preimplantation Genetic Testing Landscape

Recent years have seen a series of transformative shifts that have redefined the contours of the preimplantation genetic testing market. The industry has embraced cutting-edge technologies and methodologies that have significantly improved the precision and reliability of genetic screenings. Historically reliant on standard cytogenetic techniques, the field has now incorporated high-resolution genomic tools, leading to a paradigm shift in diagnostic accuracy and throughput.

One of the most notable advancements has been the integration of next-generation sequencing. This technology not only enhances the detection of minor chromosomal aberrations but also enables simultaneous testing for multiple genetic conditions with unmatched precision. Additionally, the evolution from traditional polymerase chain reaction (PCR)-based testing to more sophisticated genomic hybridization techniques has fostered an environment of enhanced clinical reliability.

Regulatory frameworks on a global scale are also shifting to accommodate these advancements. Newer guidelines are increasingly acknowledging the importance of genomic integrity and the necessity for comprehensive, high-fidelity preimplantation testing. Furthermore, improved collaboration between public research institutions and private enterprises has led to industry-wide synergy, spurring further innovation. The resulting paradigm shifts have, therefore, propelled the market towards an era of higher efficacy, tailored treatment modalities, and improved patient outcomes.

Key Segmentation Insights of the Preimplantation Genetic Testing Market

An in-depth examination of market segmentation reveals a nuanced landscape reflective of diverse testing techniques, advanced technologies, and varied end-use applications. The segmentation based on testing type examines the market across PGT-A, which targets aneuploidy investigation, PGT-M focused on monogenic disorder detection, and PGT-SR, designed to analyze structural rearrangements. Each category illustrates unique challenges and opportunities, driven by the specificity and accuracy required for effective diagnosis.

Furthermore, the division based on test type differentiates between preimplantation genetic diagnosis, primarily employed for detecting known genetic or chromosomal anomalies in high-risk couples, and preimplantation genetic screening, which provides a broader survey of potential genetic irregularities in embryos. This dual approach ensures that a wide range of genetic conditions can be effectively screened, offering tailored solutions for diverse patient needs.

In the realm of technology, the market segmentation covers an array of methodologies, from comparative genomic hybridization and fluorescent in-situ hybridization to next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism analysis. Advancements in these methods have significantly elevated the precision, scalability, and affordability of genetic testing procedures. The growing reliance on high-throughput technologies has not only enhanced diagnostic accuracy but has also paved the way for further scientific innovations.

Another critical aspect is the segmentation based on offerings, which scrutinizes the market through the lens of instruments, reagents and consumables, and specialized software. These components form the backbone of the testing process, and advancements in each segment underscore the progressive trends in automation and data analytics.

Finally, when considering the end-user perspective, the market is studied across diagnostic laboratories, fertility clinics, hospitals, and research institutes. This segmentation reinforces the wide adoption of PGT technologies, as diverse entities increasingly seek to balance clinical efficiency with technological sophistication. By understanding these multifaceted segmentation models, stakeholders can ascertain market trends, allocate resources strategically, and drive further innovation within this critical area of reproductive medicine.

Based on Testing Type, market is studied across PGT-A (Aneuploidy), PGT-M (Monogenic Disorders), and PGT-SR (Structural Rearrangements).

Based on Test Type, market is studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.

Based on Technology Type, market is studied across Comparative Genomic Hybridization, Fluorescent In-Situ Hybridization, Next-Generation Sequencing, PCR-Based Testing, and Single-Nucleotide Polymorphism.

Based on Offering, market is studied across Instruments, Reagents & Consumables, and Software.

Based on End User, market is studied across Diagnostic Laboratories, Fertility Clinics, Hospitals, and Research Institutes.

Key Regional Insights of the Global Preimplantation Genetic Testing Market

The regional dynamics of the preimplantation genetic testing market reveal a rich tapestry of growth patterns, regulatory environments, and technological adoption across various geographical areas. In the Americas, a combination of robust healthcare infrastructure, significant investments in biotechnology, and progressive public health policies has resulted in rapid market expansion. The region represents a hub of clinical excellence and technological adoption, making it one of the most dynamic players in the global scenario.

Across Europe, the Middle East, and Africa, the market is characterized by a balanced mix of established healthcare systems and emerging markets. Here, stringent regulatory standards coupled with a surge in demand for precision diagnostics drive advancements and innovation. This area, while facing varied challenges, also presents significant opportunities through public-private partnerships and enhanced cross-border collaborations, which act as catalysts for market growth.

In the Asia-Pacific region, rapid urbanization, increasing awareness about reproductive health, and soaring investments in healthcare technologies have contributed to a vibrant market landscape. The convergence of technological know-how and increased demand for elite medical services has made this region a fertile ground for the adoption of preimplantation genetic testing. As healthcare systems in these regions continue to evolve, the market is anticipated to benefit from an influx of new players and innovative diagnostic solutions, further reinforcing its potential on the global stage.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Preimplantation Genetic Testing Market

The competitive landscape in the preimplantation genetic testing market is marked by a diverse array of global players, each contributing to the rapid evolution of diagnostic technologies and clinical methodologies. Companies such as Abbott Laboratories and Agilent Technologies, Inc. have been front-runners, leveraging extensive research and innovation to deliver advanced genetic testing solutions. Their efforts are complemented by the expertise of organizations like Bio-Techne Corporation and Bioarray S.L., who continue to push the envelope in assay development and genomic analytics.

Emerging as significant competitors, enterprises such as EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, and Genea Limited have established a formidable presence in the sector through integrated platforms that combine clinical diagnostics with next-generation sequencing. GENETiKS, Illumina, Inc., and Invicta Genetics have further revolutionized the market by streamlining data analysis and enhancing the precision of genetic screenings.

Invitae Corporation and Juno Genetics, US Inc. are noteworthy for their contributions in facilitating accessible genetic diagnostics, while Laboratory Corporation of America Holdings and MedGenome Labs Ltd. have been instrumental in bridging the gap between cutting-edge research and clinical application. In addition, established giants such as Merck KGaA, Natera, Inc., and NextGen Genetics Holdings, LLC have strategically expanded their service portfolios to include a range of sophisticated genetic testing options.

Alongside these, companies like Ovation Fertility, PacGenomics, PerkinElmer, Inc., and Progyny, Inc. have garnered significant attention for their innovations in fertility-focused genetic diagnostics. Qiagen N.V., Quest Diagnostics Incorporated, and Reproductive Genetic Innovations, LLC have further fortified the market with robust testing solutions, while SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., and The Cooper Companies Inc. lead efforts in integrating software advancements with biological testing. Not to be overlooked, Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd. round out a competitive landscape where collaborative innovation drives both technological improvements and market penetration.

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders seeking to navigate the evolving landscape of preimplantation genetic testing successfully, several actionable recommendations stand out. One key strategy is to prioritize investment in research and development. By allocating resources to advanced genomic technologies, companies can not only enhance diagnostic accuracy but also pioneer breakthrough applications that address emerging clinical needs. Embracing innovation in next-generation sequencing and complementary technologies can facilitate the creation of more robust, user-friendly testing platforms.

Moreover, fostering collaborative partnerships between diagnostic laboratories, research institutions, and clinical service providers will be crucial in accelerating product development and streamlining regulatory pathways. Industry leaders should also focus on integrating digital solutions and artificial intelligence to optimize both data management and interpretation. By doing so, the process of genomic analysis can be made more efficient, leading to faster turnaround times and more personalized patient care.

Another critical recommendation is to enhance market penetration through strategic geographic expansion. By investing in regions with high growth potential, such as emerging markets in the Asia-Pacific and the rapidly evolving sectors in Europe, Middle East, and Africa, companies can tap into an expanding customer base. Aligning product lines with local regulatory frameworks and clinical needs will further ensure that innovations are well received in diverse markets.

Finally, it is imperative to maintain stringent quality control measures and adhere to international regulatory standards. This not only instills confidence among end-users but also fosters a competitive environment based on safety, accuracy, and superior clinical outcomes. By implementing these recommendations, industry leaders can position themselves at the forefront of an increasingly competitive and technologically advanced market.

Conclusion: The Future of Preimplantation Genetic Testing

Preimplantation genetic testing is positioned at the crossroads of rapid technological evolution and pressing clinical demand. The market is thriving due to substantial advancements in genomic technology and a clearer understanding of genetic disorders that affect reproductive health. With transformative shifts in testing methodologies and an expansive segmentation framework covering various technological and application-based arenas, the market stands to benefit from both incremental and disruptive innovations.

Globally, the market is supported by vigorous regional dynamics, with significant growth observed in the Americas, Europe, Middle East & Africa, and Asia-Pacific. Each of these regions offers unique opportunities based on their regulatory frameworks, economic environments, and healthcare infrastructures. As innovative companies continue to push boundaries, the landscape has become increasingly competitive, encouraging continuous improvement and cross-sector collaboration.

Ultimately, the future of preimplantation genetic testing is one marked by increased accuracy, efficiency, and accessibility. The cumulative effect of technological advancements, broader market segmentation, and proactive regional expansion strategies promises to redefine reproductive health care. Stakeholders who embrace these trends and invest in future-focused strategies are likely to reap substantial long-term benefits, driving both improved patient outcomes and sustainable market growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Improving healthcare infrastructure and easier access to genetic testing facilities worldwide
    • 5.1.1.2. Growing demand for in-vitro fertilization (IVF) procedures requiring preimplantation genetic testing
    • 5.1.1.3. Increasing awareness about genetic disorders and their prevention among prospective parents
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of preimplantation genetic testing procedures limiting widespread accessibility and adoption
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements enhancing accuracy and speed in preimplantation genetic testing
    • 5.1.3.2. Collaborations with IVF clinics to offer bundled preimplantation genetic testing services
  • 5.1.4. Challenges
    • 5.1.4.1. Compliance with different regional regulations and ethical standards
• 5.2. Market Segmentation Analysis
  • 5.2.1. Testing Type: Increasing need for PGT-M to prevent transmitting hereditary conditions
  • 5.2.2. End User: Growing utilization of preimplantation genetic testing in fertility clinics to enhance the success rates of in vitro fertilization
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Preimplantation Genetic Testing Market, by Testing Type

• 6.1. Introduction
• 6.2. PGT-A (Aneuploidy)
• 6.3. PGT-M (Monogenic Disorders)
• 6.4. PGT-SR (Structural Rearrangements)

7. Preimplantation Genetic Testing Market, by Test Type

• 7.1. Introduction
• 7.2. Preimplantation Genetic Diagnosis
• 7.3. Preimplantation Genetic Screening

8. Preimplantation Genetic Testing Market, by Technology Type

• 8.1. Introduction
• 8.2. Comparative Genomic Hybridization
• 8.3. Fluorescent In-Situ Hybridization
• 8.4. Next-Generation Sequencing
• 8.5. PCR-Based Testing
• 8.6. Single-Nucleotide Polymorphism

9. Preimplantation Genetic Testing Market, by Offering

• 9.1. Introduction
• 9.2. Instruments
• 9.3. Reagents & Consumables
• 9.4. Software

10. Preimplantation Genetic Testing Market, by End User

• 10.1. Introduction
• 10.2. Diagnostic Laboratories
• 10.3. Fertility Clinics
• 10.4. Hospitals
• 10.5. Research Institutes

11. Americas Preimplantation Genetic Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Successful PGT-HLA procedure at Jindal IVF offers hope for families facing genetic challenges
  • 14.3.2. Strategic GenEmbryomics and Progenesis partnership pioneers IVF testing with groundbreaking genetic innovations
  • 14.3.3. Natera Inc. to acquire prenatal and carrier screening assets from Invitae, to enhance patient services and market position
  • 14.3.4. Thermo Fisher Scientific launches advanced sequencing tools for preimplantation genetic testing, enhancing fertility research and reproductive health outcomes
  • 14.3.5. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
  • 14.3.6. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
  • 14.3.7. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
  • 14.3.8. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
  • 14.3.9. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
  • 14.3.10. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Bio-Techne Corporation
• 4. Bioarray S.L.
• 5. EUROPE IVF International s.r.o.
• 6. F. Hoffmann-La Roche AG
• 7. Genea Limited
• 8. GENETiKS
• 9. Illumina, Inc.
• 10. Invicta Genetics
• 11. Invitae Corporation
• 12. Juno Genetics, US Inc.
• 13. Laboratory Corporation of America Holdings
• 14. MedGenome Labs Ltd.
• 15. Merck KGaA
• 16. Natera, Inc.
• 17. NextGen Genetics Holdings, LLC
• 18. Ovation Fertility
• 19. PacGenomics
• 20. PerkinElmer, Inc.
• 21. Progyny, Inc.
• 22. Qiagen N.V.
• 23. Quest Diagnostics Incorporated
• 24. Reproductive Genetic Innovations, LLC
• 25. SEQUENCE46, LLC
• 26. Sysmex Corporation
• 27. Takara Bio Inc.
• 28. The Cooper Companies Inc.
• 29. Thermo Fisher Scientific Inc.
• 30. Vitrolife Sweden AB
• 31. Yikon Genomics (Shanghai) Co., Ltd.